Skip to main content

Advertisement

Figure 1 | Diabetology & Metabolic Syndrome

Figure 1

From: Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats

Figure 1

Effect of timed daily bromocriptine administration on ventromedial hypothalamic catecholamines. A. SHR rats exhibited elevated VMH NE release relative to Wistar normal controls (P < 0.0001). Timed daily bromocriptine administration significantly reduced VMH MHPG of SHR rats compared with vehicle treated SHR rats (P < 0.0001). B. SHR rats exhibited significantly lower extracellular VMH HVA content compared with normal Wistar rats (p < 0.001). C. SHR rats exhibited elevated VMH 5-HIAA release relative to Wistar normal controls (P < 0.0001). Timed daily bromocriptine administration significantly reduced VMH 5-HIAA of SHR rats compared with vehicle treated SHR rats (P < 0.0001) There was no significant difference in VMH 5-HIAA levels between SHR BC treated and Wistar rats.

Back to article page